Drug prescription in Italian Residential Facilities;La prescrizione di psicofarmaci nelle Strutture Residenziali Italiane

Epidemiologia e Psichiatria Sociale

Volumn 14, Issue 2, 2005, Pages 77-90

  Tomasi, Rodolfo ^a   De Girolamo, Giovanni ^b,d,h   Santone, Giovanni ^c   Picardi, Angelo ^d   Micciolo, Rocco ^e   Semisa, Domenico ^f   Fava, Silva ^g   Picardi, A ^d   Morosini, P ^d   Micciolo, R ^e   Argentino, P ⁱ   Borsetti, G ⁱ   Casacchia, M ⁱ   Ciliberti, P ⁱ   Civenti, G ⁱ   Colotto, A ⁱ   Dell'Acqua, G ⁱ   Di Munzio, W ⁱ   Fagnano, G ⁱ   Fioritti, A ⁱ   Longhin, N ⁱ   Miceli, M ⁱ   Nicotera, M ⁱ   Pisetta, M ⁱ   Putzolu, R ⁱ   Rossi, E ⁱ   Rotunno, M E ⁱ   Semisa, D ⁱ   Tomasi, R ⁱ   Tulli, P ⁱ   Zanalda, E ⁱ   Amaddeo, F ⁱ   Barbini, C ⁱ   Basile, F ⁱ   Bazzacco, G ⁱ   Bracco, R ⁱ   Calvarese, A ⁱ   Canuso, G ⁱ   Caroppo, E ⁱ   Caserta, L ⁱ   Colangione, M ⁱ   Damiani, S ⁱ   De Donatis, T ⁱ   Di Donato, F ⁱ   Di Michele, V ⁱ   Esposito, R ⁱ   Facchini, M ⁱ   Falloon, I ⁱ   Ferraro, S ⁱ   Fracchiolla, P ⁱ   Gabriele, P ⁱ   Gallicchio, D ⁱ   Giardina, G ⁱ   Greco, A ⁱ   Grilletti, F ⁱ   Guzzo, S ⁱ   Lerario, A M ⁱ   Marinelli, M R ⁱ   Marino, C ⁱ   Monzani, E ⁱ   Picco, F ⁱ   Pinciaroli, L ⁱ   Rossetti, C A ⁱ   Rubatta, P ⁱ   Santone, G ⁱ   Scorpiniti, F ⁱ   Scrofani, V ⁱ   Stefani, M ⁱ   Svettini, A ⁱ   Zaffarano, A ⁱ   Cellini, M ⁱ   Galli, A ⁱ   Pesaresi, K ⁱ   Pitzalis, G ⁱ   Tarantino, L ⁱ   more..

^a Ospedale di Bolzano   (Italy)

^b Azienda USL di Bologna   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e UNIVERSITY OF TRENTO   (Italy)

^f Dipartimento di Salute Mentale   (Italy)

^g ASL of Ravenna   (Italy)

^h Dipartimento di Salute Mentale   (Italy)

ⁱ NONE

Author keywords

Polypharmacy; Prescription pattern; Psychotropic drugs; Residential facilities

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRESCRIPTION; QUESTIONNAIRE; RESIDENTIAL HOME; TARDIVE DYSKINESIA;

EID: 21344458185     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1121189X0000628X     Document Type: Article

References (66)

1. Addington D.D., Azorin J.M., Falloon I.R.H., Gerlach J., Hirsch S.R. & Siris S.G. (2002). Clinical issues related to depression in schizophrenia: an international survey of psychiatrists. Acta Psychiatrica Scandinavica 105, 189-195.
2. Barbui C., D'Avanzo B., Frattura L. & Saraceno B. (1999). QUALYOP Project 2: monitoring the dismantling of Italian psychiatric hospitals. Psychotropic drug use in 1072 inpatients. Pharmacoepidemiology and Drug Safety 8, 331-337.
3. Barbui C., Danese A., Guaiana G., Mapelli L., Miele L., Monzani E. & Percudani M. (2002). Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry 35, 239-243.
4. Basan A. & Leucht S. (2004). Valproate for schizophrenia (Cochrane Review). Cochrane Library, Issue 1.
5. Bellantuono C., Reggi V., Rognoni G. & Muscettola G. (1981). Comparisons of practice in hospitals and community mental health centers. In Epidemiological Impact of Psychotropic Drugs (ed. G. Tognoni, C. Bellantuono and M. Lader). Elsevier: Amsterdam.
6. Benson K. & Hartz A.J. (2000). A comparison of observational studies and randomized, controlled trials. New England Journal of Medicine 342, 1878-1886.
7. Blanco C., Laje G., Olfson M., Marcus S.C. & Pincus H.A. (2002.) Trends in the treatment of bipolar disorders by outpatients psychiatrists. American Jurnal of Psychiatry 159, 1005-1010.
8. Bolts S., Hines H. & Littrell R. (2003). Antipsychotic polypharmacy in the ambulatory care setting, 1993-2000. Psychiatric Services 54, 1086-1090.
9. Buchanan R.W., Kreyenbuhl J., Zito J.M. & Lehman A. (2002). Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. American Journal of Psychiatry 159, 1035-1043.
10. Castle D., Morgan V. & Jablensky A. (2002). Antipsychotic use in Australia: the patients' perspective. Australian and New Zealand Journal of Psychiatry 36, 633-641.
11. Centorrino F., Goren J.L., Hennen J., Salvatore P., Kelleher J.P. & Baldessarini R.J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. American Journal of Psychiatry 161, 700-706.
12. Chong M., Tan C.H., Fujii S., Yang S., Ungvari G., Tianmei S., Chung E.K., Sim K., Tsang H. & Shinfuku N. (2004). Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry and Clinical Neuroscience 58, 61-67.
13. Clark R.E., Bartels S.J., Mellman T.A. & Peacock W.J. (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophrenia Bulletin 28, 75-84.
14. Concato J., Shah N. & Horwitz R.I. (2000). Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 342, 1887-1892.
15. Cosentino M., Leoni O., Rispoli L., Pellegrini C., Finavera L., Lecchini S. & Frigo G. (1995). A 1- year study of drug prescriptions and adverse drug reactions in psychiatric hospital practice. Pharmacoepidemiology and Drug Safety 5, 377-384.
16. Covell N.H., Jackson C.T., Evans A.C. & Essock S.M. (2002). Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bulletin 28, 17-29.
17. Craig T.J. & Behar R. (1980). Trends in the prescription of psychotropic drugs (1970-1977) in a state hospital. Comprehensive Psychiatry 21, 336-345.
18. de Girolamo G. & Cappiello V. (1993). Gli studi di drug-utilization in psichiatria: una review. Rivista di Psichiatria 28, 133-142.
19. de Girolamo G., Williams P. & Cappiello V. (1987) Psychotropic drug utilization and "audit" in two Italian psychiatric services. Psychological Medicine 17, 989-997.
20. de Girolamo G., Picardi A., Micciolo R., Falloon I., Fioritti A. & Morosini P. for the Italian PROGRES study group (2002). Residential care in Italy: a national survey of non-hospital facilities. British Journal of Psychiatry 181, 220-225.
21. Escamilla M.A. (2001). Diagnosis and treatment of mood disorders that co-occur with schizophrenia. Psychiatric Services 52, 911-919.
22. Freudenreich O. & Goff D.C. (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combination. Acta Psychiatrica Scandinavica 106, 323-330.
23. Gruppo Nazionale PROGRES (2001). Le strutture residenziali psichiatriche in Italia. I risultati della fase 1 del progetto PROGRES. Epidemiologia e Psichiatria Sociale 10, 260-275.
24. Harrington M., Leliott P., Paton C., Konsolaki M., Sensky T. & Okocha C. (2002a). Variation between services in polypharmacy and combined high dose of antipsychotic drug prescribed for in-patients. Psychiatric Bulletin 26, 418-420.
25. Harrington M., Lelliott P., Paton C., Okocha C., Duffett R. & Sensky T. (2002b). The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin 26, 414-418.
26. Kingsbury S.J., Yi D. & Simpson G.M. (2001). Rational and irrational polypharmacy. Psychiatric Services 52, 1033-1036.
27. Lam R.W., Peters R., Sladen-Dew N. & Altman S. (1998). A community-based clinic survey of antidepressant use in persons with schizophrenia. Canadian Journal of Psychiatry 43, 513-516.
28. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O. & Kreyenbul J. (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161, Suppl 2, 1-56.
29. Lelliott P., Paton C., Harrington M., Konsolaki M., Sensky T. & Okocha C. (2002). The influence of patients variables in polypharmacy and combined high dose of antipsychotic drug prescribed for in-patients. Psychiatric Bulletin 26, 411-414.
30. Levine J., Chengappa R., Brar J.S., Gershon S., Yablonsky E., Stapf D. & Kupfer D.J. (2000). Psychotropic drug prescription patterns among patiens with bipolar I disorder. Bipolar Disorders 2, 120-130.
31. Lim P.Z., Tunis S.L., Edell W.S., Jensik S.E. & Tonen M. (2001). Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disorders 3, 165-173.
32. Lindenmayer J.P. & Kotsaftis A. (2000). Use of sodium valproate in violent and aggressive behaviours: a critical review. Journal of Clinical Psychiatry 61, 123-128.
33. Martin A., Van Hoof T., Stubbe D., Sherwin T. & Scahill L. (2003). Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid Managed Care. Psychiatric Services 54, 72-77.
34. McCue R.E., Waheed R. & Urcuyo L. (2003). Polypharmacy in patients with schizophrenia. Journal of Clinical Psychiatry 64, 984-989.
35. Michel K. & Kolakowska T. (1981). A survey of prescribing psychotropic drugs in two British hospitals. British Journal of Psychiatry 138, 217-221.
36. Morosini P.L., Magliano L., Brambilla L., Ugolini S. & Pioli R. (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 101, 323-329.
37. Mulholland C. & Cooper S. (2000). The symptom of depression in schizophrenia and its management. Advances in Psychiatric Treatment 6, 169-177.
38. Munizza C., Tibaldi G., Bollini P., Pirfo E., Punzo F. & Gramaglia F. (1995). Prescription pattern of antidepressants in out-patient psychiatric practice. Psychological Medicine 25, 771-778.
39. Muscettola G., Bollini P. & Pampallona S. (1991). Pattern of neuroleptic drug use in Italian mental health services. Pharmacoepidemiology 25, 296-301.
40. Muscettola G., Barbato G., Pampallona S., Casiello M. & Bollini P. (1999). Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. Journal of Clinical Psychophamacology 19, 203-208.
41. Muscettola G., Casiello M., Bollini P., Sebastiani G., Pampallona S. & Tognoni G. (1987). Pattern of therapeutic intervention and role of psychiatric settings: a survey in 2 regions of Italy. Acta Psychiatrica Scandinavica 75, 55-61.
42. NICE: National Institute of Clinical Excellence (2002). Clinical Guideline I. Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. National Institute of Clinical Excellence: London.
43. Norusis M.J. (1998). SPSS for Windows Professional and Advanced Statistics, Release 8.0. SPSS Inc.: Chicago.
44. Nottested J.A. & Linaker O.M. (2003). Psychotropic drug use among people with intellectual disability before and after deinstitutionalization. Journal of Intellectual Disability Research 47, 464-471.
45. O'Driscoll C, & Leff J. (1993). The TAPS Project. 8: Design of the research study on the long-stay patients. British Journal of Psychiatry, Suppl, 19, 18-24.
46. Paton C, Lelliott P., Harrington M., Okocha C., Sensky T. & Duffett R. (2003). Patterns of antipsychotic and anticholinergic prescribing for hospital inpalients. Journal of Psychopharmacology 17, 223-229.
47. Percudani M. & Barbui C. (2003). Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. Journal of Clinical Psychiatry 64, 1293-1299.
48. Procyshyn R.M., Kennedy N.B., Tse G. & Thompson B. (2001). Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Canadian Journal of Psychiatry 46, 334-339.
49. Ray J.G. (2002). Evidence in upheaval: incorporating observational data into clinical practice. Archives of Internal Medicine 162, 249-254.
50. Rittmannsberger H. (2002). The use of drug monotherapy in psychiatric inpatient treatment. Progress in Neuro-Psychopharmachology & Biological Psychiatry 26, 547-551.
51. Segal S.P., Cohen D. & Marder S.R. (1992). Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective. American Journal of Public Health 82, 846-852.
52. Soares K.V. & McGrath J.J. (2000). Anticholinergic medication for neuroleptic-induced tardive dyskinesias. Cochrane Library, Issue 2.
53. Stahl S.M. (2002a). Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatrica Scandinavica 106, 321-322.
54. Stahl S.M. (2002b). Antipsychotic polypharmacy: squandering precious resources? Journal of Clinical Psychiatry 63, 93-94.
55. Suzuki T., Uccida H., Tanaka K.F., Nomura K., Takano H., Tanabe A., Watanabe K., Yagi G. & Kashima H. (2204). Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. International Journal of Nenropsychopharmacology 7, 1-10.
56. Taylor D., McConnell D., McConnell H. & Kerwin R. (2001). The Maudsley 2001 Prescribing Guidelines, Martin Dunitz: London.
57. Tibaldi G., Munizza C., Bollini P., Pirfo E., Punzo F. & Gramaglia F. (1997). Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont. Psychiatric Services 48, 213-217.
58. Tognoni G. (1999). Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. European Journal of Clinical Pharmacology 55, 685-690
59. Trieman N. & Leff J. (2002) Long-term outcome of long-stay psychiatric in-patients considered unsuitable to live in the community. British Journal of Psychiatry 181, 428-432.
60. Voirol P., Robert P.A., Meister P., Oros L. & Baumann P. (1999). Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 32, 29-37.
61. Waddington J.L., Youssef H.A. & Kinsella A. (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-years prospective study. British Journal of Psychiatry 173, 325-329.
62. Williams P., Bellantuono C., Fiorio R. & Tansella M. (1986) Psychotropic drugs use in Italy: national trends and regional differences. Psychological Medicine 16, 841-850.
63. Wilson W.H., Ban T.A. & Guy W. (1985). Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices. Neuropsychobiology 14, 75-82.
64. Wing J.K., Beevor A.S., Curtis R.H., Park S.B., Hadden S. & Burns A. (1998). Health of the Nation Outcome Scales (HoNOS). Research and development. British Journal of Psychiatry 172, 11-18.
65. Wyosowski D.K. & Baum C. (1989). Antipsychotic drug use in the United States, 1976-85. Archives of General Psychiatry 46, 929-932.
66. Zarate C.A. & Quiroz J.A. (2003). Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disorders 5, 217-225.